患有2型糖尿病患者在残疾发作后的药物坚持:使用全国数据进行差异差异分析
Szu-Han Chen1, Miaw-Chwen Lee2,3,4, Christy Pu5
1Department of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
BMC medicine
|March 6, 2024
概括
残疾发病显著减少了2型糖尿病药物治疗的坚持,在特定的残疾类型中看到的影响更大. 这凸显了为管理这两种情况的个人制定量身定制的支持策略的必要性.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 管理伴随性糖尿病和残疾存在重大挑战.
- 在2型糖尿病中,残疾开始对药物坚持的影响还不清楚.
- 调查这种关系对于有效的患者管理至关重要.
研究的目的:
- 为了确定残疾发作是否会影响对2型糖尿病药物的坚持.
- 根据残疾类型分析依从性降低的变化.
主要方法:
- 利用台湾国家残疾登记和国家医疗保险研究数据库 (2013-2020).
- 匹配了2型糖尿病患者,有或没有随后的残疾发作.
- 使用差异分析来评估药物持有率 (MPR).
主要成果:
- 失能开始导致1年MPR减少5.76% (P < 0.001).
- 观察到两年MPR显著下降13.21% (P < 0.001).
- 器官残疾,多重残疾,罕见疾病和持续的植物状态显示了最大的坚持减少.
结论:
- 失能发作对2型糖尿病药物治疗的坚持有负面影响.
- 根据残疾类型,坚持减少的差异很大.
- 政策必须解决残疾人面临的具体挑战,以改善药物坚持.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Diabetes: Management and Pharmacotherapy
282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K


